Zeer uitgebreid verwoord Aston. Aanbeveling.
Heb zelf nog een mooie follow-up over meneer Porges en zijn eerdere vraag aan AbbVie.
28 juli 2017 Q2 Conference Call AbbVie.
Our next question comes from Geoff Porges of Leerink Partners. Your line's open.
Geoffrey C. Porges - Leerink Partners LLC
Thank you very much for taking the question. Two quick questions, one, you have the rights to the Galapagos cystic fibrosis program and you haven't talked about that much on this call, certainly, and recently. I'm wondering how you view the recent announcements from the Vertex program and whether that's changed your appetite for investing in the Galapagos program and your expectations and when you expect to start Phase 3 for that program.
Michael E. Severino, M.D. - AbbVie, Inc.
Okay. This is Mike. I'll take CF first. You know, our CF program is a program that we feel very good about. It's still in early phase studies. And so for a company of our size, we don't always spend a lot of time talking about our very early phase work, but that doesn't mean that we're not excited about it. I think there's a real opportunity there. I think the target has a lot of the characteristics of things we're really good at doing, engineering very, very specific and high-quality small molecules together with our partner on this, Galapagos. I think there clearly is an unmet medical need. Obviously, there have been advancements in the field, and that's good for patients, but there's more room to go. And so we think that we can contribute there.
With respect to the Vertex data, and the Vertex data are strong, but we expected those data to come out and we expected them to be strong. We still believe that there is headroom above that that can benefit patients, and we can help meet that need. It's our mid-phase trials that are going to provide that answer. And we and Galapagos are working diligently to move into that phase of development. With respect to Phase 3, I think it's a bit early to predict timing on Phase 3 right now.
Is meneer Porges beschermheer van Vertex..?
AbbVie laat 3 maanden geleden weten dat zij geloven in hun benaderingswijze, waarvan Galapagos het merendeel van werk vol verricht, doch is AbbVie met veel mensen betrokken bij project.
Zie de abstracts.
3 triples in de mand voor Galapagos/AbbVie.
Kansen te over om Vertex' positie te bedreigen en dat voelen ze.
Stel je voor dat Galapagos met triple 2222+3067+3221 (de voorziene super combi) alsnog met goedgekeurde IND's een fase 1b/2a kan starten in USA+EU zomer/najaar 2018.
Die stap kan nog altijd gemaakt worden bij tijdige indiening en afronding fase 1 GLPG3221.
Dan zit Vertex echt op hete kolen.